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Objective: To consolidate current opinion on trial methodology of disease modifying therapies (DMTs) for
Parkinson’s disease (PD) and establish consensus on a core protocol for an adaptive platform trial.
Background: Current neuroprotective trial delivery in PD is slow and inef cient. An adaptive trial platform
may offer bene ts but requires consensus on a core protocol [1]. In collaboration with The Cure Parkinson’s
Trust, a Delphi study is being conducted with a broad range of international stakeholders to seek opinion on
aspects of trial design for neuroprotective trials in PD.
Method: Clinicians, industry and funding agency representatives as well as People with Parkinson’s (PwP)
and their care partners are invited to take part. In order to ensure the process comprehensively addresses
issues important to all involved stakeholders, participants are encouraged to suggest topics for inclusion in
the Delphi process as part of the  rst survey. Participants are asked to rate the importance of trial design
aspects on a 9-point semantic differential scale and are encouraged to give reasons for their choices. After
being presented with a representation of group scores and feedback, participants are asked to re-rate. This
process is repeated 4 times or until 70% of at least 3 participant groups score within the same 3 point range.
Results: This process will result in the identi cation of aspects important to stakeholders in neuroprotective
trials of PD. The information will be made available to working groups dedicated to the design and initiation
of an adaptive platform trial for disease modifying therapies in PD.
Conclusion: We are seeking opinion from international stakeholders and experts in neuroprotective trials on
important aspects of trial design. This is the  rst step towards the development of an internationally
endorsed protocol for an adaptive trial platform in PD.
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